Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - NUGENEREX IMMUNO-ONCOLOGY, INC. | ex31_2.htm |
| EX-31.1 - EXHIBIT 31.1 - NUGENEREX IMMUNO-ONCOLOGY, INC. | ex31_1.htm |
| 10-K - 10-K - NUGENEREX IMMUNO-ONCOLOGY, INC. | ngio073120form10k.htm |
Exhibit 32
CERTIFICATIONS
Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. ss. 1350, as adopted), Joseph Moscato, Chief Executive Officer, President and Principal Financial Officer of NuGenerex Immuno-Oncology, Inc. (the "Company"), hereby certifies that, to the best of their knowledge:
1. The Company's 10-K for the fiscal year ended July 31, 2020 to which this Certification is attached as Exhibit 32 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of the period covered by the Report.
| DATE: October 29, 2020 | By: | /s/ Joseph Moscato |
| Joseph Moscato | ||
| President & Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| DATE: October 29, 2020 | By: | /s/ Mark Corrao |
| Mark Corrao | ||
| Chief Financial Officer | ||
| (Principal Financial Officer) |